Drug Trial Radar · NCT00375830
Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
Last checked: Nov 20, 2026Latest source record: Dec 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
114
Actual
Start
Jan 2006
Primary completion
Apr 17, 2017
Study completion Mar 14, 2019
Sponsor
- Lead sponsor
- Stanford UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 13, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer.
Conditions
- Cancer
Interventions
Bone scanProcedure
Scan to diagnose a number of bone conditions including cancer or metastasis
99mTc-methyl diphosphonateDrug
Radiolabel for bone scan procedures
Positron Emission Tomography (PET) scanProcedure
Scan to detect gamma rays emitted by a positron-emitting radioligand such as 18F
18F-Fludeoxyglucose (18F-FDG)Drug
Radiolabel for positron emission tomography scan procedures
Computed Tomography (CT) scanProcedure
Scan to detect \& analyze X-rays
18F-Sodium Fluoride (18F-NaF)Drug
Radiolabel for CT and PET scans, \& as a contrast agent for MRI scans.
Whole Body Magnetic Resonance Imaging (WB-MRI) scanProcedure
Whole Body Magnetic Resonance Imaging (WB-MRI) scan: Scan that uses strong magnetic fields \& radio waves to generate images of the organs in the body.
Gadopentetate dimeglumineDrug
A gadolinium-based contrast agent for MRI
GadofosvesetDrug
A gadolinium-based contrast agent for MRI
GadobutrolDrug
A gadolinium-based contrast agent for MRI
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1 - NaF PET/CT vs 99mTc-MDP Bone ScintigraphyTime frame: 30 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Stanford University School of Medicine
Stanford, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.